Effects of Haemodialysis Session on Plasma Beta-Endorphin, ACTH and Cortisol in Patients with End-Stage Renal Disease

REFERENCES

• Avioli LV, Teibelbaum SL. The renal osteodystrophies: In: Brenner, Rector. The Kidney, Vol. 2, Philadelphia: Saunders, 1976; 1242–1591.
   Google Scholar
• Azonin N, Krieger DT. Plasma immunoreactive β-endorphin is elevated in uremia. Clin Endocrinol 1983; 18: 459–464.
   PubMed Web of Science ®Google Scholar
• Carlstrom K, Pousette A, Stege R, Linholm A. Serum hormone levels in man with end stage renal disease. Scand J Urol Nephrol 1990; 24: 75–78.
   PubMed Web of Science ®Google Scholar
• Carr DB, Bullen BA, Skinar GS, et al. Physical conditioning facilitates the exercise-induced secretion of beta-endorphin and beta-lipotropin. N Engl J Med 1981; 305: 560–561.
   PubMed Web of Science ®Google Scholar
• Cohen M, Pikar D, Dubois M, Roth YF, Naber D, Bunney W. Surgical stress and endorphins. Lancet 1981; 1: 213–214.
   PubMed Web of Science ®Google Scholar
• Elias AN, Vaziri ND, Masky M. Plasma β-endorphin and β-lipotropin in patients with end stage renal disease effects of hemodialysis. Nephron 1986; 43: 173–176.
   PubMed Web of Science ®Google Scholar
• Emmanovel DS, Lindheimer MD, Katz AI. Pathogenesis of endocrine abnormalities in uremia. Endocr Rev 1980; 1: 28–44.
   PubMedGoogle Scholar
• Feldman HA, Singer I. Endocrinology and metabolism in uremia and dialysis: a clinical review. Medicine (Baltimore) 1974; 54: 345–376.
   Web of Science ®Google Scholar
• Fukata J, Imura H, Nakao K. Cytokines as mediators in the regulation of the hypthalamic-pituitary-adrenocortical function. J Endocrinol Invest 1993; 16: 141–155.
   Google Scholar
• Grant AC, Rodger RSC, Mitchell R, Gibson S, White A, Robertson WR. Hypothalamo-pituitary-adrenal axis in uremia: evidence for primary adrenal dysfunction. Nephrol Dial Transplant 1993; 8: 307–310.
   PubMedGoogle Scholar
• Guillemin R, Vargo T, Rossier J, et al. Beta-endorphin and adreno-corticotropin are secreted concomitantly by the pituitary gland. Science 1977; 197: 1367–1369.
   PubMed Web of Science ®Google Scholar
• Hebelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumour necrosis factor. Kidney Int 1990; 37: 116–125.
   PubMed Web of Science ®Google Scholar
• Hegbrant J, Thysell H, Hekman R. Plasma levels of vasoreactive regulatory peptides in patients receiving regular hemodialysis treatment Scand J Urol Nephrol 1992; 26: 169–176.
   Google Scholar
• Krieger DT. Endorphins and enkephalins. Disease a Month. Chicago: Year Book Medical Publishers, 1982.
   Google Scholar
• Lim VS, Fang VS, Katz AI, Refetoff S. Thyroid dysfunction in chronic renal failure. A study of the pituitary-thyroid axis and peripheral turnover kinetics of thyroxine and triiogothyronine. J Clin Invest 1977; 60: 522–534.
   PubMed Web of Science ®Google Scholar
• McDonald WJ, Golper TA, Mass RD, et al. Adreno-corticotropin-cortisol axis abnormalities in hemodialysis patients. J Clin Endocrinol Metab 1980; 50: 92–95.
   Google Scholar
• Mastrogiacomo I, De Besi L, Zucchetta P, et al. Male hypogonadism of uremic patients on hemodyalisis. Arch Androl 1988; 20: 171–175.
   PubMed Web of Science ®Google Scholar
• Morley JE, Barame Tsky NG, Winget TD, et al. Endocrine effects of naloxone-induced opiate receptor blokade. J Clin Endocrinol Metab 1980; 50: 251–257.
   PubMed Web of Science ®Google Scholar
• Nakao K, Nakai Y, Jngami H, Oki S, Fukata J, Imura H. Substantial rise of plasma beta-endorphin levels after insulin-induced hypoglycemia in human subjects. J Clin Endocrinol Metab 1979; 49: 838–841.
   PubMed Web of Science ®Google Scholar
• Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1β, TNFa and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890–894.
   PubMed Web of Science ®Google Scholar
• Ramirez G, O'Neill WJr, Bloomer HA. Thyroid dysfunction in uremia: evidence for thyroid and hypophyseal abnormalities. Ann Intern Med 1976; 84: 672–676.
   PubMed Web of Science ®Google Scholar
• Ramirez G, Gomez-Sanchez C, Meikle WA, Jubiz W. Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis. Arch Intern Med 1982; 142: 1448–1452.
   PubMedGoogle Scholar
• Ramirez G, Bittle PA, Sanders H, Rabb HAA, Beren BB. The effects of corticotropin and Growth hormone releasing hormones on their respective secretory axis in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin. J Clin Endocrinol Metab 1994; 78: 63–69.
   PubMed Web of Science ®Google Scholar
• Scavo D, Barletta C, Vagiri D, Letizia C. Adrenocorticotropic hormone, beta-endorphin, Cortisol, growth hormone and prolactin circulating levels in nineteen atheletes before and after half-marathon and marathon. J Sports Med Phys Fitness 1993; 31: 401–406.
   Web of Science ®Google Scholar
• Siamopulos KC, Daraamis M, Kyriaki D, et al. Pituitary adrenal responsiveness to corticotropin-releasing hormone in chronic uremic patients. Perit Dial Int 1990; 10: 153–156.
   PubMed Web of Science ®Google Scholar
• Smith R, Grossman R, Gaillard R, et al. Studies on circulating met-enkephalin and β-endorphin: normal subjects and patients with renal and adrenal disease. Clin Endocrinol 1981; 15: 291–300.
   PubMed Web of Science ®Google Scholar
• Stewart-Bentley M, Gans D, Horton R. Regulation of gonadal function in uremia. Metabolism 1975; 23: 1065–1072.
   Web of Science ®Google Scholar
• Wallace EZ, Rosman P, Toshav N, Sacerdote A, Balthazar A. Pituitary-adrenocortical function in chronic renal failure: studies of episodic secretion of Cortisol and dexamethasone suppressibility. J Clin Endocrinol Metab 1980; 50: 46–51.
   PubMed Web of Science ®Google Scholar